HemaGenetics Technologies

HemaGenetics Technologies was a Canadian public company that presented itself as a biotechnology company focused on hematology-related research opportunities. Public disclosures indicate it entered into a transaction to acquire HemaGenetic Research Group in April 2019, but there is limited evidence of a conventional therapeutic development pipeline, clinical assets, or commercialized products. In July 2020, the company changed its name to Canam Biotech Inc., indicating that HemaGenetics Technologies no longer operates under its original name. Available public information suggests it functioned more as a small-cap public vehicle pursuing biotech-related corporate transactions than as an established drug developer with a documented clinical pipeline.